KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (2016 - 2025)

Nektar Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $20.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $20.4 million for Q4 2025, up 64.54% from a year ago — trailing twelve months through Dec 2025 was $20.4 million (up 64.54% YoY), and the annual figure for FY2025 was $20.4 million, up 64.54%.
  • Shares Outstanding for Q4 2025 was $20.4 million at Nektar Therapeutics, up from $19.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for NKTR hit a ceiling of $190.8 million in Q3 2023 and a floor of $12.2 million in Q1 2024.
  • Median Shares Outstanding over the past 5 years was $183.0 million (2021), compared with a mean of $109.2 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 93.55% in 2024 and later surged 64.54% in 2025.
  • Nektar Therapeutics' Shares Outstanding stood at $185.5 million in 2021, then grew by 1.67% to $188.6 million in 2022, then tumbled by 93.23% to $12.8 million in 2023, then decreased by 2.92% to $12.4 million in 2024, then surged by 64.54% to $20.4 million in 2025.
  • The last three reported values for Shares Outstanding were $20.4 million (Q4 2025), $19.7 million (Q3 2025), and $12.5 million (Q2 2025) per Business Quant data.